0	6	Cobalt	Cobalt	NNP
7	23	chloride-induced	chloride-induced	JJ
24	33	signaling	signaling	NN
34	36	in	in	IN
37	48	endothelium	endothelium	NN
49	56	leading	lead	VBG
57	59	to	to	TO
60	63	the	the	DT
64	73	augmented	augmented	JJ
74	83	adherence	adherence	NN
84	86	of	of	IN
87	93	sickle	sickle	JJ
94	97	red	red	JJ
98	103	blood	blood	NN
104	109	cells	cell	NNS
110	113	and	and	CC
114	130	transendothelial	transendothelial	JJ
131	140	migration	migration	NN
141	143	of	of	IN
144	157	monocyte-like	monocyte-like	JJ
158	163	HL-60	hl-60	NN
164	169	cells	cell	NNS
170	172	is	be	VBZ
173	180	blocked	block	VBN
181	183	by	by	IN
184	196	PAF-receptor	PAF-receptor	NNP
197	207	antagonist	antagonist	NN
207	208	.	.	.

210	212	In	in	IN
213	221	response	response	NN
222	224	to	to	TO
225	232	hypoxia	hypoxia	NN
232	233	,	,	,
234	240	sickle	sickle	JJ
241	244	red	red	JJ
245	250	blood	blood	NN
251	256	cells	cell	NNS
257	258	(	(	(
258	260	SS	SS	NNP
261	264	RBC	RBC	NNP
264	265	)	)	)
266	269	and	and	CC
270	280	leukocytes	leukocyte	NNS
281	288	exhibit	exhibit	VBP
289	298	increased	increase	VBN
299	308	adherence	adherence	NN
309	311	to	to	TO
312	315	the	the	DT
316	324	vascular	vascular	JJ
325	336	endothelium	endothelium	NN
336	337	,	,	,
338	343	while	while	IN
344	354	diapedesis	diapedesis	NN
355	357	of	of	IN
358	368	leukocytes	leukocyte	NNS
369	376	through	through	IN
377	380	the	the	DT
381	386	blood	blood	NN
387	393	vessel	vessel	NN
394	403	increases	increase	NNS
403	404	.	.	.

405	412	However	however	RB
412	413	,	,	,
414	417	the	the	DT
418	426	cellular	cellular	JJ
427	436	signaling	signaling	NN
437	447	pathway(s)	pathway(s)	NN
448	454	caused	cause	VBN
455	457	by	by	IN
458	465	hypoxia	hypoxia	NN
466	468	is	be	VBZ
469	475	poorly	poorly	RB
476	486	understood	understand	VBN
486	487	.	.	.

488	490	We	we	PRP
491	499	utilized	utilize	VBD
500	505	CoCl2	cocl2	NN
506	508	as	as	IN
509	510	a	a	DT
511	518	mimetic	mimetic	JJ
519	527	molecule	molecule	NN
528	531	for	for	IN
532	539	hypoxia	hypoxia	NN
540	542	to	to	TO
543	548	study	study	VB
549	557	cellular	cellular	JJ
558	567	signaling	signaling	NN
568	576	pathways	pathway	NNS
576	577	.	.	.

578	580	We	we	PRP
581	586	found	find	VBD
587	591	that	that	IN
592	594	in	in	IN
595	600	human	human	JJ
601	610	umbilical	umbilical	JJ
611	615	vein	vein	NN
616	627	endothelial	endothelial	JJ
628	633	cells	cell	NNS
634	635	(	(	(
635	640	HUVEC	HUVEC	NNP
640	641	)	)	)
641	642	,	,	,
643	648	CoCl2	cocl2	NN
649	651	at	at	IN
652	653	2	2	CD
654	656	mM	mm	NN
657	670	concentration	concentration	NN
671	678	induced	induce	VBD
679	682	the	the	DT
683	690	surface	surface	NN
691	701	expression	expression	NN
702	704	of	of	IN
705	706	a	a	DT
707	713	subset	subset	NN
714	716	of	of	IN
717	721	CAMs	CAM	NNP
722	723	(	(	(
723	729	VCAM-1	VCAM-1	NNP
729	730	)	)	)
731	734	and	and	CC
735	745	activation	activation	NN
746	748	of	of	IN
749	762	transcription	transcription	NN
763	769	factor	factor	NN
770	779	NF-kappaB	nf-kappab	NN
780	782	in	in	IN
783	786	the	the	DT
787	794	nuclear	nuclear	JJ
795	803	extracts	extract	NNS
804	806	of	of	IN
807	812	HUVEC	HUVEC	NNP
812	813	.	.	.

814	825	Furthermore	furthermore	RB
825	826	,	,	,
827	832	CoCl2	CoCl2	NNP
833	837	also	also	RB
838	844	caused	cause	VBD
845	859	time-dependent	time-dependent	JJ
860	868	tyrosine	tyrosine	NN
869	884	phosphorylation	phosphorylation	NN
885	887	of	of	IN
888	905	mitogen-activated	mitogen-activated	JJ
906	913	protein	protein	NN
914	915	(	(	(
915	918	MAP	MAP	NNP
918	919	)	)	)
920	926	kinase	kinase	NNP
927	934	isoform	isoform	NN
935	939	ERK2	erk2	NN
940	947	without	without	IN
948	961	significantly	significantly	RB
962	971	affecting	affect	VBG
972	976	ERK1	erk1	NN
976	977	,	,	,
978	988	indicating	indicate	VBG
989	993	ERK2	erk2	NN
994	996	is	be	VBZ
997	1000	the	the	DT
1001	1010	preferred	prefer	VBN
1011	1020	substrate	substrate	NN
1021	1024	for	for	IN
1025	1033	upstream	upstream	JJ
1034	1040	kinase	kinase	NNP
1041	1043	of	of	IN
1044	1047	the	the	DT
1048	1052	MAPK	MAPK	NNP
1053	1060	pathway	pathway	NN
1060	1061	.	.	.

1062	1072	Inhibitors	inhibitor	NNS
1073	1075	of	of	IN
1076	1079	MAP	MAP	NNP
1080	1086	kinase	kinase	NNP
1087	1088	(	(	(
1088	1095	PD98059	PD98059	NNP
1095	1096	)	)	)
1097	1099	or	or	CC
1100	1119	platelet-activating	platelet-activating	JJ
1120	1126	factor	factor	NN
1127	1128	(	(	(
1128	1133	PAF)-	paf)-	NN
1134	1142	receptor	receptor	NN
1143	1153	antagonist	antagonist	NN
1154	1155	(	(	(
1155	1161	CV3988	cv3988	NN
1161	1162	)	)	)
1163	1172	inhibited	inhibit	VBD
1173	1176	the	the	DT
1177	1190	CoCl2-induced	cocl2-induced	JJ
1191	1200	NF-kappaB	NF-kappaB	NNP
1201	1211	activation	activation	NN
1212	1215	and	and	CC
1216	1222	VCAM-1	vcam-1	NN
1223	1233	expression	expression	NN
1233	1234	.	.	.

1235	1244	Augmented	augmented	JJ
1245	1255	expression	expression	NN
1256	1258	of	of	IN
1259	1265	VCAM-1	vcam-1	NN
1266	1269	led	lead	VBD
1270	1272	to	to	TO
1273	1282	increased	increase	VBN
1283	1285	SS	SS	NNP
1286	1289	RBC	RBC	NNP
1290	1298	adhesion	adhesion	NN
1298	1299	,	,	,
1300	1311	inhibitable	inhibitable	JJ
1312	1314	by	by	IN
1315	1316	a	a	DT
1317	1323	VCAM-1	vcam-1	NN
1324	1332	antibody	antibody	NN
1332	1333	.	.	.

1334	1346	Additionally	additionally	RB
1346	1347	,	,	,
1348	1353	CoCl2	CoCl2	NNP
1354	1360	caused	cause	VBD
1361	1362	a	a	DT
1363	1367	two-	two-	CD
1368	1370	to	to	TO
1371	1380	threefold	threefold	JJ
1381	1389	increase	increase	NN
1390	1392	in	in	IN
1393	1396	the	the	DT
1397	1401	rate	rate	NN
1402	1404	of	of	IN
1405	1421	transendothelial	transendothelial	JJ
1422	1431	migration	migration	NN
1432	1434	of	of	IN
1435	1448	monocyte-like	monocyte-like	JJ
1449	1454	HL-60	hl-60	NN
1455	1460	cells	cell	NNS
1461	1464	and	and	CC
1465	1466	a	a	DT
1467	1477	twentyfold	twentyfold	JJ
1478	1486	increase	increase	NN
1487	1489	in	in	IN
1490	1505	phosphorylation	phosphorylation	NN
1506	1508	of	of	IN
1509	1517	platelet	platelet	NN
1518	1529	endothelial	endothelial	JJ
1530	1534	cell	cell	NN
1535	1543	adhesion	adhesion	NN
1544	1553	molecules	molecule	NNS
1554	1555	(	(	(
1555	1562	PECAM-1	pecam-1	NN
1562	1563	)	)	)
1563	1564	.	.	.

1565	1568	The	the	DT
1569	1585	transendothelial	transendothelial	JJ
1586	1595	migration	migration	NN
1596	1598	of	of	IN
1599	1608	monocytes	monocyte	NNS
1609	1612	was	be	VBD
1613	1622	inhibited	inhibit	VBN
1623	1625	by	by	IN
1626	1628	an	an	DT
1629	1637	antibody	antibody	NN
1638	1640	to	to	TO
1641	1648	PECAM-1	pecam-1	NN
1648	1649	.	.	.

1650	1654	Both	both	CC
1655	1670	phosphorylation	phosphorylation	NN
1671	1673	of	of	IN
1674	1681	PECAM-1	pecam-1	NN
1682	1685	and	and	CC
1686	1702	transendothelial	transendothelial	JJ
1703	1712	migration	migration	NN
1713	1715	of	of	IN
1716	1725	monocytes	monocyte	NNS
1726	1728	in	in	IN
1729	1737	response	response	NN
1738	1740	to	to	TO
1741	1746	CoCl2	CoCl2	NNP
1747	1751	were	be	VBD
1752	1761	inhibited	inhibit	VBN
1762	1764	by	by	IN
1765	1772	protein	protein	NN
1773	1779	kinase	kinase	NNP
1780	1789	inhibitor	inhibitor	NN
1790	1791	(	(	(
1791	1800	GF109203X	GF109203X	NNP
1800	1801	)	)	)
1802	1805	and	and	CC
1806	1815	augmented	augment	VBN
1816	1818	by	by	IN
1819	1826	protein	protein	NN
1827	1838	phosphatase	phosphatase	NN
1839	1848	inhibitor	inhibitor	NN
1849	1850	(	(	(
1850	1859	Calyculin	Calyculin	NNP
1860	1861	A	A	NNP
1861	1862	)	)	)
1862	1863	.	.	.

1864	1867	Our	our	PRP$
1868	1872	data	datum	NNS
1873	1881	suggests	suggest	VBZ
1882	1886	that	that	IN
1887	1900	CoCl2-induced	cocl2-induced	JJ
1901	1909	cellular	cellular	JJ
1910	1917	signals	signal	NNS
1918	1927	directing	direct	VBG
1928	1937	increased	increase	VBN
1938	1948	expression	expression	NN
1949	1951	of	of	IN
1952	1958	VCAM-1	vcam-1	NN
1959	1961	in	in	IN
1962	1967	HUVEC	HUVEC	NNP
1968	1975	involve	involve	VBP
1976	1986	downstream	downstream	JJ
1987	1997	activation	activation	NN
1998	2000	of	of	IN
2001	2004	MAP	MAP	NNP
2005	2011	kinase	kinase	NNP
2012	2015	and	and	CC
2016	2025	NF-kappaB	NF-kappaB	NNP
2025	2026	,	,	,
2027	2032	while	while	IN
2033	2036	the	the	DT
2037	2052	phosphorylation	phosphorylation	NN
2053	2055	of	of	IN
2056	2063	PECAM-1	pecam-1	NN
2064	2070	occurs	occur	VBZ
2071	2073	as	as	IN
2074	2075	a	a	DT
2076	2082	result	result	NN
2083	2085	of	of	IN
2086	2096	activation	activation	NN
2097	2099	of	of	IN
2100	2103	PKC	PKC	NNP
2103	2104	.	.	.

2105	2107	We	we	PRP
2108	2116	conclude	conclude	VBP
2117	2121	that	that	IN
2122	2134	PAF-receptor	PAF-receptor	NNP
2135	2145	antagonist	antagonist	NN
2146	2154	inhibits	inhibit	VBZ
2155	2158	the	the	DT
2159	2165	CoCl2-	cocl2-	NN
2166	2168	or	or	CC
2169	2184	hypoxia-induced	hypoxia-induced	JJ
2185	2193	increase	increase	NN
2194	2196	in	in	IN
2197	2200	the	the	DT
2201	2209	adhesion	adhesion	NN
2210	2212	of	of	IN
2213	2215	SS	SS	NNP
2216	2219	RBC	RBC	NNP
2219	2220	,	,	,
2221	2228	PECAM-1	pecam-1	NN
2229	2244	phosphorylation	phosphorylation	NN
2244	2245	,	,	,
2246	2249	and	and	CC
2250	2253	the	the	DT
2254	2265	concomitant	concomitant	JJ
2266	2282	transendothelial	transendothelial	JJ
2283	2292	migration	migration	NN
2293	2295	of	of	IN
2296	2305	monocytes	monocyte	NNS
2305	2306	.	.	.